Body Image Disorder in Anorexia Nervosa and Virtual Reality

Anorexia Clinical Trial

— REVAM  

Official title:

Body Image Disorder in Anorexia Nervosa and Virtual Reality

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03118921
• Other study ID #: REVAM
• Status: Terminated
• Phase: N/A
• Start date: April 20, 2017
• Est. completion date: October 31, 2019

Study information

• Verified date: December 2021
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation of the tolerance and acceptability of the virtual representation of its body image.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: October 31, 2019
• Est. primary completion date: October 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 16 Years to 40 Years

Eligibility

Inclusion Criteria:

• Women, aged between 16 and 40
• Post-puberty
• Pure restrictive anorexia nervosa, diagnosis by the DSM-V
• BMI <17.5
• Patient attending an outpatient clinic at the Bohars Psychiatric Hospital in France
• Having signed the Informed Consent Form
• For minor patients, signing the form of informed consent of both parents

Exclusion Criteria:

• Associated eating disorder (bulimia, or the binge eating / purging form of anorexia nervosa),
• Psychiatric disorders (characterized depressed, anxiety disorder)
• Neurological Disorders
• Mental retardation
• Abuse or addiction to alcohol
• Abuse or dependence on psychoactive substances in the previous year.
• Patient with a protective justice measure

Related Conditions & MeSH terms

• Anorexia
• Anorexia Nervosa
• Body Dysmorphic Disorders

Intervention

Device:
• Virtual reality
The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.

Locations

Country	Name	City	State
France	CHRU Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Self-questionnaire assessing tolerance	Patients will have to respond to a self-administered questionnaire assessing tolerance	Day 15
Primary	Self-questionnaire assessing acceptability	Patients will have to respond to a self-administered questionnaire assessing acceptability	Day 15
Secondary	Feeling of presence	Patients will respond to a self-questionnaire of feeling of presence	Day 15
Secondary	Subjective experience by EDI-2 questionnaire	Pre- and post-test comparison of body dissatisfaction by EDI-2 questionnaire.	Day 15
Secondary	Subjective experience by BSQ questionnaire	Pre- and post-test comparison of body dissatisfaction by BSQ questionnaire.	Day 15